李晔雄，博士，籍贯湖南，肿瘤放疗专家。永利集团3044官网欢迎您协和医科大学肿瘤医院教授、主任医师，博士生导师。1984年湖南医科大学医疗系毕业获得学士学位，1990年获中国协和医科大学放射肿瘤学硕士学位，1997年获瑞士洛桑大学放射肿瘤学博士学位，1998年在美国德克萨斯大学M.D. Anderson癌症中心从事博士后研究。2003年起聘任正高，2020年为协和长聘教授。2000年任科主任。一直从事放射肿瘤学临床和转化研究。

主要研究领域为恶性肿瘤的放疗，开展和应用最先进放疗技术，改进治疗方法，着重探索淋巴瘤临床病理和生物学特征，建立风险分层治疗原则和放疗指南，建立乳腺癌术后短疗程大分割照射方案等，居国际领先水平。

1. Jin J#*, Tang Y#, Hu C, Jiang LM, Jiang J, Li N, Liu WY, Chen SL, Li H, Lu NN, Cai Y, Li YH, Zhu Y, Cheng GH, Zhang HY, Wang X, Zhu SY, Wang J, Li GF, Yang JL, Zhang K, Chi Y, Yang L, Zhang HZ, Zhou ZX, Zhou AP, Zou SM, Fang H, Wang SL, Zhang HZ*, Wang XS*, Wei LC*, Wang WL*, Liu SX*, Gao YH*, Li YX*. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022, 40:1681-1692. (IF=50.717, PIII)

2. Chen B#, Wu JX#, Cheng SH, Wang LM, Rong WQ,Wu F, Wang SL, Jin J, Liu YP, Song YW, Ren H, Fang H, Tang Y, Li N, Li YX*, Wang WH*. Phase 2 study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma. Hepatol. 2021, 74(5):2595-2604. (IF=17.298)

3. Wang SL# Fang F#, Hu C, Song YW, Wang WH, Jin J, Liu YP, Ren H, Liu J, Li GF, Du XH, Hui X, Tang Y, Jing H, Ma YC, Huang Z, Chen B, Tang Y, Li N, Lu NN, Qi SN, Yang Y, Sun GY, Liu XF, Li YX*. Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicentre randomized controlled trial from China. J Clin Oncol. 2020, 38:3604-3614. (IF=44.544, PIII, R)

4. Wang SL#, Fang H#, Song YW, Wang WH, Hu C, Liu YP, Jin J, Liu XF, Yu ZH, Ren H, Li N, Lu NN, Tang Y, Tang Y, Qi SN, Sun GY, Peng R, Li S, Chen B, Yang Y, Li YX*. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for high-risk breast cancer patients: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019, 20:352-360. (IF=32.277, PIII, ESI, R)

5. Yang Y#, Cao JZ#, Lan SM, Wu JX, Wu T, Zhu SY, Qian LT, Hou XR, Zhang FQ, Zhang YJ, Zhu Y, Xu LM, Yuan ZY, Qi SN, and Li YX*. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type NK/T-cell lymphoma. JAMA Oncol. 2017, 3(1):83-91. (IF=16.559)

6. Yang Y#, Zhu Y#, Cao JZ, Zhang YJ, Xu LM, Yuan ZY, Wu JX, Wang W, Wu T, Lu B, Zhu SY, Qian LT, Zhang FQ, Hou XR, and Li YX*. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015, 126(12):1424-1432. (IF=9.762)

7. Wang ZY#, Liu QF, Wang H, Jin J, Wang WH, Wang SL, Song YW, Liu YP, Fang H, Ren H, Wu RY, Chen B, Zhang XM, Lu NN, Zhou LQ, Li YX*. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extra nodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012, 120(10):2003-2010. (IF=10.337)

8. Wang ZY#, Li YX*, Wang WH, Jin J, Wang H, Song YW, Liu QF, Wang SL, Liu YP, Qi SN, Fang H, Liu XF, and Yu ZH. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood. 2009, 114(23):4771-4776. (IF=10.566, R)

9. Li YX*#, Fang H, Liu QF, Lu J, Qi SN, Wang H, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Feng XL, and Yu ZH. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood. 2008, 112(8):3057-3064. (IF=10.466, R)

10. Li YX*#, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH, Lu N, and Yu ZH. Radiotherapy as primary treatment for stage IE and IIE nasal NK/T-cell lymphoma. J Clin Oncol. 2006, 24(1):181-189. (IF=10.863, C100, R)